Aditxt, Inc. ADTX

Aditxt, Inc. (ADTX) lost its Nasdaq listing after seven reverse splits failed to restore compliance, with retail investors remaining bullish on the stock. Nasdaq delisting sharply cuts liquidity, visibility and institutional access for ADTX shares.

ADTX stock surges 40% overnight as a new 10% holder emerges after Aditxt completes Ignite Proteomics SPAC deal. New 10% holder after SPAC deal drives major stock surge and shifts market dynamics for ADTX.

Aditxt, Inc. (ADTX) and Ignite announce merger plans involving a strategic partner. Merger announcement signals major strategic move that can significantly alter company trajectory and investor sentiment.

Aditxt Inc. revealed a new strategic collaboration and technology milestone driving sharp increase in ADTX trading volume and share price. Collaboration and milestone represent major strategic moves expected to significantly boost revenue trajectory and investor sentiment.

Aditxt signed a definitive agreement valuing Ignite Proteomics at approximately $150 million. The $150 million valuation agreement marks a substantial strategic expansion for Aditxt.

Aditxt, Inc. has appointed Saundra Pelletier, CEO of Evofem Biosciences, to its Board of Directors. Pelletier brings over three decades of experience in women's health and has led Evofem through significant milestones, including the launch of PHEXXI®, a hormone-free contraceptive. Aditxt aims to transition to a commercial stage company and expand its focus on women's health through a proposed acquisition of Evofem, targeting a close in the second half of 2025, contingent on shareholder approval and capital raising. The appointment of a seasoned executive and the potential acquisition of Evofem are significant strategic moves that could enhance Aditxt's market position and product offerings.

Ignite Proteomics launches prospective 10,000-patient oncology registry to assess functional proteomics for cancer therapy selection. Large-scale oncology registry directly advances Aditxt subsidiary capabilities and market positioning in precision cancer care.

Aditxt Inc appoints Jeffrey M Busch as interim CEO. Busch founded and formerly led a $1B NYSE enterprise that delivered ~8.5% dividends to shareholders. CEO appointment with noted credentials may shift strategy and influence near-term investor views without transforming operations.

Aditxt, Inc. (NASDAQ: ADTX) announces a 1-for-27 reverse stock split effective at the open of trading on May 18, 2026. Reverse stock splits like this often address listing compliance but trigger negative market sentiment and potential share price volatility.

Dana-Farber Cancer Institute study validates Ignite Proteomics’ RPPA platform for predicting T-DXd (Enhertu®) therapy response in metastatic breast cancer patients. Dana-Farber validation boosts credibility of ADTX's proteomics platform in precision oncology, likely enhancing partnerships and market sentiment.

Aditxt Inc. (ADTX) acquires Ignite Proteomics to solve a key cancer care challenge by optimizing therapy selection. Acquisition bolsters Aditxt's oncology portfolio with proteomics tech for personalized therapy, driving significant strategic growth.

Aditxt, Inc. (NASDAQ: ADTX) announces a 1-for-8 reverse stock split effective at the market open on March 9, 2026. The reverse stock split aims to increase share price for potential NASDAQ compliance but often signals financial distress with moderate impact on market sentiment and performance.

Aditxt, Inc. (ADTX) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market dynamics have contributed to its increased visibility among traders and investors. Increased trading activity indicates moderate investor interest, which may influence market sentiment and short-term performance.

Aditxt, Inc. (ADTX) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market performance have contributed to its visibility among investors, indicating potential shifts in market sentiment and engagement with its offerings. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

Aditxt, Inc. (NASDAQ: ADTX) has announced a 1-for-113 reverse stock split that will take effect at the open of trading on November 3, 2025. This move is part of the company's strategy to regain compliance with NASDAQ listing requirements and improve its stock price. The reverse stock split is expected to have a moderately noticeable influence on the company's market perception and compliance status.

Aditxt, Inc. (ADTX) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market performance have contributed to its visibility among investors, indicating potential shifts in market sentiment and engagement with its stock. Increased trading activity suggests a moderately noticeable influence on market sentiment and investor interest.

Aditxt, Inc.'s subsidiary, Pearsanta, has initiated enrollment for its first human study focused on a blood-based diagnostic for endometriosis, a condition that affects 190 million women globally and represents a $1.45 billion market. This study aims to develop a non-invasive diagnostic tool to improve the detection and management of endometriosis. The initiation of a human study for a blood-based diagnostic could significantly enhance Aditxt's product offerings and market position in a substantial healthcare market.

Aditxt, Inc. (ADTX) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and interest among investors. The company's recent developments and market performance have contributed to its visibility, attracting attention from traders and analysts alike. Increased trading activity may influence market sentiment and investor interest, but it is not expected to fundamentally alter the company's trajectory.

Evofem anticipates the approval of its merger with Aditxt, Inc. at the upcoming stockholder meeting, which is expected to enhance both companies' strategic positions and market opportunities. The merger aims to create synergies that could lead to improved financial performance and innovation in their respective fields. The merger is likely to significantly impact Aditxt's future performance and market positioning.

Aditxt’s subsidiary, Adimune, is advancing its method of reprogramming the immune system using DNA instructions, with a portfolio of 96 granted and 22 pending patents. This innovation targets the autoimmunity market, projected to exceed $160 billion by 2030. The substantial patent portfolio and focus on a rapidly growing market indicate a significant potential impact on Aditxt's future performance.

Evofem reported positive financial results for the second quarter of 2025, highlighting increased revenue and improved operational efficiency. The company provided a business update, outlining strategic initiatives and future growth plans. Key metrics showed significant progress, indicating a strong market position and potential for continued success. Positive financial results and strategic initiatives may moderately influence the company's future performance.

Aditxt’s subsidiary, Pearsanta, Inc., has engaged Spartan Capital as the lead underwriter for its planned IPO. The funds raised will support the clinical validation and commercial rollout of its Mitomic™ platform technology, aimed at the early detection of cancers and other diseases. The planned IPO and subsequent rollout of innovative technology could significantly impact Aditxt's future performance and market position.

Aditxt’s subsidiary, Pearsanta, has received an invitation to submit a full proposal for a pilot award from the U.S. Department of Defense. This award is aimed at developing the Mitomic® Ovarian Test, which could enhance ovarian cancer detection and management. Securing a pilot award from the U.S. Department of Defense could significantly enhance Aditxt's product development and market positioning in the healthcare sector.

PHEXXI, a non-hormonal birth control brand by Evofem Biosciences, has gone viral on TikTok with over 10 million views, sparking a national conversation on microfeminism. The brand encourages women to share their daily practices of microfeminism, leading to widespread media coverage from BuzzFeed and Scary Mommy. CEO Saundra Pelletier emphasizes that PHEXXI represents women's autonomy and choice in health. Evofem is set to be acquired by Aditxt, which aims to enhance its women's health program, with the merger expected to close in the second half of 2025. The acquisition of Evofem by Aditxt and the viral success of PHEXXI could significantly enhance Aditxt's market position and investor sentiment in women's health.

Aditxt, Inc. (NASDAQ: ADTX) announced that Co-founder and CEO Amro Albanna will present at Wall Street Reporter’s NEXT SUPER STOCK livestream on June 26, 2025, at 1:00 p.m. ET. The presentation will cover Aditxt’s innovation acceleration business model, the status of its programs focused on autoimmunity and early cancer detection, and the pending acquisition of Evofem Biosciences, Inc. The acquisition aims to introduce a program dedicated to women’s health, with a targeted close in the second half of 2025, subject to various conditions including shareholder approval and capital raising. Aditxt operates a platform that promotes health innovations through collaboration among research institutions, industry partners, and shareholders. The pending acquisition of Evofem Biosciences could significantly enhance Aditxt's product offerings and market position in women's health.

Saundra Pelletier, CEO of Evofem Biosciences, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, are set to join Aditxt for a weekly update on June 6. Their participation indicates a collaborative effort and potential strategic discussions that may influence Aditxt's direction and partnerships. The involvement of notable industry leaders may enhance Aditxt's market positioning and collaborative opportunities.

Appili Therapeutics has provided an update regarding its arrangement with Aditxt, Inc. The details of the arrangement and its implications for both companies were outlined, indicating ongoing collaboration and strategic alignment in their respective operations. The arrangement may moderately influence Aditxt's competitive positioning and operational aspects.

Aditxt, Inc. has announced the termination of its Arrangement Agreement with Appili Therapeutics, which will eliminate approximately $16 million in closing obligations. The decision follows multiple amendments to the agreement since its announcement in April 2024, as Aditxt determined it was no longer strategically aligned to proceed. The termination will be effective May 31, 2025. Aditxt is also pursuing a Merger Agreement with Evofem Biosciences, which involves cash payments of approximately $17 million, contingent on raising sufficient capital and shareholder approvals. The termination of the agreement and ongoing merger efforts may moderately influence Aditxt's financial performance and strategic direction.

Aditxt, Inc. (NASDAQ: ADTX) announced a virtual Aditxt Weekly Update featuring Dr. Shahrokh Shabahang and Dr. Friedrich Kapp to discuss advancements related to ADI-100™, a lead therapeutic candidate from its subsidiary Adimune. ADI-100™ is an investigational gene therapy aimed at restoring immune tolerance in autoimmune diseases and organ transplantation, utilizing a proprietary Apoptotic DNA Immunotherapy™ platform. Aditxt is also pursuing strategic partnerships to enhance its health innovation programs, including agreements with Appili Therapeutics and Evofem Biosciences, subject to funding and shareholder approvals. The discussion of ADI-100™ and strategic partnerships indicates significant potential for future growth and market impact.

Dr. Charles Howe from the Mayo Clinic’s Neuroimmunology Department will join Aditxt Inc. for a weekly update on May 2, 2025, to discuss the results of a newly announced preclinical study sponsored by Aditxt’s subsidiary, Adimune™. The involvement of a prominent figure from the Mayo Clinic in discussing preclinical study results may enhance Aditxt's credibility and influence its market position.